Clinical Trials Directory

Trials / Completed

CompletedNCT02632266

Effect of Extensively Hydrolyzed Liquid Human Milk Fortifier on Growth and Tolerance in Moderately Premature Infants

Status
Completed
Phase
Phase 4
Study type
Interventional
Enrollment
40 (actual)
Sponsor
University of Kansas Medical Center · Academic / Other
Sex
All
Age
28 Weeks – 34 Weeks
Healthy volunteers
Accepted

Summary

The purpose of this study is for the researchers to examine the safety and efficacy of liquid human milk fortifier (HMF) in moderately preterm infants compared to powdered human milk fortifier.

Detailed description

This is a prospective, randomize, double-blinded study in preterm infants born between 28-34 weeks gestation admitted to the NICU at the University of Kansas Hospital. After obtaining informed consent, babies will be randomized to either liquid or powdered HMF using opaque, sealed envelopes with preassigned randomization. The feeding protocol as established in the KU NICU will be followed, beginning with initiation of trophic feeds, and advancement of enteral feeds depending on the gestational age and preceding illnesses. Once infants reach 80ml/kg/day of enteral feeds, human milk will be fortified to 22 kilocalories by adding either liquid or powdered fortifier. The beginning of the study(Study day 1) will be defined as reaching and tolerating 100ml/kg/day of 24 kilocalorie human milk fortified with either liquid or powdered fortifier. Enteral feeds will be advanced per unit protocol until they reach 150-160ml/kg/day and 110-120 kcal/kg/day. the volume of feeds will be adjusted based on the documented weight to provide energy and protein requirements as recommended by the ESPGHAN guidelines. Babies will be followed up until the time of NICU discharge.

Conditions

Interventions

TypeNameDescription
DIETARY_SUPPLEMENTPowder HMFpowder human milk fortifier
DIETARY_SUPPLEMENTLiquid HMFLiquid human milk fortifier

Timeline

Start date
2015-07-01
Primary completion
2019-05-01
Completion
2019-05-01
First posted
2015-12-16
Last updated
2020-09-03

Locations

1 site across 1 country: United States

Source: ClinicalTrials.gov record NCT02632266. Inclusion in this directory is not an endorsement.